By 2030, it is anticipated that the UK infectious disease therapeutics market will reach a value of $3.75 Bn from $3.12 Bn in 2022, growing at a CAGR of 2.4% during 2022-2030. Infectious Disease Therapeutics in the UK is dominated by a few domestic pharmaceutical companies such as GlaxoSmithKline, Faron Pharmaceuticals and Emergent BioSolutions. The infectious disease therapeutics market in the UK is segmented into different therapeutic areas and different treatment types. The major factors affecting the UK infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious disease treatment in various areas of the UK.
By 2030, it is anticipated that the UK infectious disease therapeutics market will reach a value of $3.75 Bn from $3.12 Bn in 2022, growing at a CAGR of 2.4% during 2022-2030.
The UK is a high-income, developed island country spanning an archipelago including Great Britain, located in Western Europe comprising England, Scotland, Wales, and Northern Ireland. Communicable diseases, often known as infectious diseases, are illnesses that can be passed from person to person directly or indirectly. Diseases such as measles or mumps can spread by coughing, sneezing or touching infected surfaces. Sexually transmitted diseases (STIs) and hepatitis are spread via bodily fluids like blood or sperm.
Several improvements in infectious disease therapies have occurred in recent years, including the creation of novel antibiotics and antiviral medications, as well as advances in immunotherapy and vaccine development. Immunotherapy is a new therapeutic approach that leverages the body's immune system to combat infectious diseases. The development of immunotherapies for diseases such as HIV and hepatitis C has received special attention in the UK. UK's government spends 12 % of its GDP on healthcare.
Market Growth Drivers Analysis
In response to the COVID-19 pandemic, the UK has made significant investments in the development and manufacturing of COVID-19 vaccines and therapies. Several medications, including remdesivir, dexamethasone, and tocilizumab, have been authorised for use in the UK to treat COVID-19. The Small Business Research Initiative (SBRI) and the Longitude Prize are two initiatives sponsored by the UK government to assist in the development of novel antibiotics. The UK has been involved in the development of various novel malaria treatments. Tafenoquine, a novel medicine that has been found to be effective against malaria and has recently been approved for use in the UK, is one example. Cutting-edge pharmaceuticals sectors in the UK give a push to the expansion. These aspects could boost UK infectious disease therapeutics market.
Market Restraints
The UK's low productivity and training deficit are not favourable to innovation. Developing new pharmaceuticals and treatments necessitates adhering to regulatory rules established by organisations such as the UK's Medicines and Healthcare products Regulatory Agency (MHRA). These requirements can be complicated and time-consuming, resulting in delays and higher expenses. These factors may deter new entrants into the UK infectious disease therapeutics market.
Key Players
December 2022: Following the European Commission's licence in November 2022, GSK has announced that the UK's Medicines and Healthcare products Regulatory Agency (MHRA) has approved Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults aged 18 and above in Great Britain.
In the UK, the regulation of infectious disease therapeutics is primarily overseen by the Medicines and Healthcare products Regulatory Agency (MHRA). The MHRA is in charge of guaranteeing the safety, effectiveness, and high quality of all medicines and medical equipment, including those used to treat infectious diseases. In order to be licenced for use in the UK, infectious disease treatments must first go through a rigorous regulatory process that includes clinical studies and other testing to ensure their safety and efficacy. Following the approval of a product, the MHRA continues to monitor its safety and quality through post-marketing surveillance. Other UK regulatory bodies that may be involved in the regulation of infectious disease therapeutics, in addition to the MHRA, include the National Institute for Health and Care Excellence (NICE), which provides guidance on the use of new treatments within the NHS, and the Health and Safety Executive (HSE), which regulates the use of hazardous substances in the workplace.
In the UK, the National Health Service (NHS) manages the reimbursement of infectious disease medicines through a system known as the National Institute for Health and Care Excellence (NICE). NICE assesses new medications and therapies for efficacy, safety, and cost-effectiveness before recommending whether they should be paid for by the NHS.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?